Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanobiotix ( (NBTX) ) has issued an update.
On November 24, 2025, Nanobiotix announced significant progress in its operations and financial strategy, including the closing of a non-dilutive royalty financing deal with HealthCare Royalty valued at up to $71 million. This move is expected to support the company’s long-term growth. Additionally, the company reported advancements in its JNJ-1900 (NBTXR3) clinical development program, including the transfer of the NANORAY-312 study sponsorship to Johnson & Johnson and the presentation of new data from a Phase 1 esophageal cancer study. The company also highlighted progress in its Curadigm Nanoprimer program, with new patent applications and collaborations. These developments position Nanobiotix for accelerated growth in 2026, with ongoing and upcoming clinical trials expected to provide further insights into the potential of its innovative cancer treatments.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, with a focus on pioneering physics-based therapeutic approaches to improve treatment outcomes for cancer and other major diseases. The company is listed on Euronext Paris and the Nasdaq Global Select Market, and it has subsidiaries in Cambridge, Massachusetts. Nanobiotix owns over 25 umbrella patents related to nanotechnology platforms with applications in oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 93,064
Technical Sentiment Signal: Buy
Current Market Cap: $1B
See more insights into NBTX stock on TipRanks’ Stock Analysis page.